If you need help accessing our website, call 855-698-9991
Affiliated Provider
Affiliated providers provide medical care at an NYU Langone location or a private practice, and are not employed by NYU Langone Health.

Cristian C. Papazoglu Statescu, MD, PhD

Affiliated Provider
Affiliated providers provide medical care at an NYU Langone location or a private practice, and are not employed by NYU Langone Health.
  • Specialties: Hematology, Medical Oncology
  • Treats: Adults
  • Languages: English, Romanian

Driven by an insatiable curiosity, I have long been dedicated to understanding the mechanisms of complex systems. This passion led me to pursue a medical degree, which naturally aligned with my thirst for knowledge, fascination with the intricacies of the human body, and deep compassion for others.

Throughout medical school, I encountered the stark reality that many diseases remain without known cures or established causes, which only intensified my commitment to the field of medicine. After earning my PhD in cancer genetics from Stony Brook University, I expanded my knowledge by gaining valuable insights through research in both academic and industry settings. These experiences solidified my desire to merge clinical practice with research, enabling me to provide compassionate and cutting-edge care to patients confronting hematologic and oncologic challenges.

At NYU Langone and Bellevue Hospital Center, I care for patients with both benign and malignant hematologic disorders, as well as those with genitourinary cancers, including prostate, kidney, bladder, and testicular cancers.

I believe that every patient is unique, and their care should reflect that individuality. This drives me to take a personalized approach to treatment, tailoring each plan to the specific characteristics of the patient and their disease. Our patient-centered philosophy extends beyond simply treating cancer; we are committed to addressing the emotional, psychological, and social dimensions of each individual’s experience. When patients choose our care, they gain not only access to highly skilled specialists but also to the latest advancements in research and cutting-edge clinical trials. Together, we provide a holistic, compassionate, and innovative approach to healing—one that strives to make a lasting impact on both the science of medicine and the lives of those we treat.


Conditions and Treatments

Conditions
  • acute myelogenous leukemia
  • aids-related malignancies
  • anemia
  • bladder cancer
  • central nervous system lymphoma
  • chronic myelogenous leukemia (cml)
  • cutaneous t-cell lymphoma
  • diffuse large b-cell lymphoma
  • essential thrombocythemia (et)
  • female germ cell tumor
  • hodgkin lymphoma
  • kidney cancer
  • male germ cell tumor
  • multiple myeloma
  • myelodysplastic syndromes (mds)
  • myelofibrosis
  • myeloproliferative disorder
  • non-hodgkin lymphoma
  • polycythemia vera
  • prostate cancer
  • sickle cell anemia
  • testicular cancer
  • thrombocytopenia
  • thrombosis
  • ureter cancer

Positions
Board Certifications
  • American Board of Internal Medicine (Medical Oncology), 2020
  • American Board of Internal Medicine (Hematology), 2019
  • American Board of Internal Medicine - Internal Medicine, 2017
Education and Training
  • Fellowship, Montefiore Medical Center/Albert Einstein College of Medicine, Hematology & Medical Oncology, 2019
  • Residency, Montefiore Medical Center/Albert Einstein College of Medicine, Internal Medicine, 2016
  • PhD from SUNY - Stony Brook, 2008
  • MD from Carol Davila University, 2003

Is this your profile?

Edit profile

Please call the office for information about accepted insurance plans.

Cristian C. Papazoglu Statescu, MD, PhD does not accept insurance.

Academic office

462 First Avenue, OBV-C&D Building

5th Floor, 556

New York, NY 10016

Phone

212-562-1135

Fax

212-263-8210

  • A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

    Learn More
  • A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors

    Learn More
  • EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence

    Learn More
View All Research Studies (6)

Read All Publications (8)